Pipeline
| Program | Indication | Collaborator | Phase | Description | Status / Timeline |
|---|---|---|---|---|---|
|
ABS-111 |
Idiopathic Pulmonary Fibrosis (IPF) |
Stanford |
Phase 1b |
FDA-approved investigational therapy advancing under the SAFE-IPF trial. |
Trial initiation Q4 2025 |
|
ABS-111 |
Pulmonary Arterial Hypertension (PAH) |
Stanford |
Phase 1b |
FDA-approved investigational therapy advancing under the STOP-PAH trial. |
Trial initiation Q4 2025 |
|
ABS-121 |
Fibro-Inflammatory Lung Diseases |
Phase 1a/1b (Hybrid) |
First-in-human small-molecule program targeting novel fibro-inflammatory mechanisms. |
Trial initiation Q2 2026 |